Semler Scientific (NASDAQ:SMLR) Trading Down 6.3% - Time to Sell?

Key Points

• Semler Scientific's stock fell by 6.3% on Friday, trading at $36.43, significantly below its previous close of $38.89.
• Research analysts have varied opinions on the stock, with Wall Street Zen downgrading it to a "sell" rating while Benchmark set a price target of $101.00.
• The company's latest earnings report showed a (0.76) EPS and revenues of $8.84 million, indicating financial challenges with a negative net margin of 60.69%.
• Institutional investors and hedge funds own approximately 49.37% of Semler Scientific's stock, indicating significant market interest despite the recent drop.

Semler Scientific Inc. (NASDAQ:SMLR - Get Free Report) shares dropped 6.3% during mid-day trading on Friday . The company traded as low as $37.26 and last traded at $36.43. Approximately 60,799 shares were traded during trading, a decline of 91% from the average daily volume of 696,389 shares. The stock had previously closed at $38.89.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Wall Street Zen cut shares of Semler Scientific from a "buy" rating to a "sell" rating in a research report on Thursday, May 22nd. Benchmark started coverage on Semler Scientific in a research note on Tuesday, July 8th. They issued a "buy" rating and a $101.00 price target for the company. Finally, Maxim Group upgraded Semler Scientific to a "strong-buy" rating and set a $95.00 target price for the company in a report on Wednesday, July 9th.

Semler Scientific Stock Down 4.7%

The business has a 50-day simple moving average of $38.82 and a two-hundred day simple moving average of $40.90. The stock has a market capitalization of $510.85 million, a P/E ratio of -14.17 and a beta of 1.39. The company has a quick ratio of 0.51, a current ratio of 0.52 and a debt-to-equity ratio of 0.59.

Semler Scientific (NASDAQ:SMLR - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.76) EPS for the quarter. The business had revenue of $8.84 million for the quarter. Semler Scientific had a positive return on equity of 19.75% and a negative net margin of 60.69%.

Hedge Funds Weigh In On Semler Scientific

Several hedge funds have recently added to or reduced their stakes in the stock. Deltec Asset Management LLC lifted its stake in Semler Scientific by 112.0% in the second quarter. Deltec Asset Management LLC now owns 100,932 shares of the company's stock valued at $3,910,000 after buying an additional 53,332 shares during the period. SummerHaven Investment Management LLC raised its position in shares of Semler Scientific by 2.0% during the second quarter. SummerHaven Investment Management LLC now owns 23,570 shares of the company's stock worth $913,000 after purchasing an additional 464 shares during the period. Rhumbline Advisers raised its position in shares of Semler Scientific by 24.6% during the first quarter. Rhumbline Advisers now owns 7,418 shares of the company's stock worth $269,000 after purchasing an additional 1,466 shares during the period. Flaharty Asset Management LLC acquired a new stake in shares of Semler Scientific during the first quarter worth about $243,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Semler Scientific by 47.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,965 shares of the company's stock worth $144,000 after purchasing an additional 1,269 shares during the period. Institutional investors and hedge funds own 49.37% of the company's stock.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.